Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s13311-017-0512-4 http://scihub22266oqcxt.onion/10.1007/s13311-017-0512-4 C5509621!5509621!28194663     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Neurotherapeutics 2017 ; 14 (3): 784-91 Nephropedia Template TP {{tp|p=28194663|t=2017. Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study |pdf=|usr=}}{{28194663}} gab.com Text Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study JO: Neurotherapeutics http://www.kidney.de/pget.php?&tw=1&pmid=28194663 #FOAvip Whether antiplatelet agents have a preventive effect on cognitive function remains unknown. We examined the potential association between the use of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, and the risk of dementia in an Asian population. Patients initiating cilostazol therapy between 1 January 2004 and 31 December 2009 without a prior history of dementia were identified from Taiwan's National Health Insurance database. Participants were stratified by age, sex, comorbidities, and comedication. The outcome of interest was all-cause dementia (ICD-9-CM codes 290.0, 290.4, 294.1, 331.0). Cox regression models were used to estimate the hazard ratio (HR) of dementia. The cumulative cilostazol dosage was stratified by quartile of defined daily doses using no cilostazol use as a reference. A total of 9148 participants 40 years of age or older and free of dementia at baseline were analyzed. Patients using cilostazol (n?=?2287) had a significantly decreased risk of incident dementia compared with patients not using the drug [n?=?6861; adjusted HR (aHR) 0.75; 95% confidence interval (CI) 0.61?0.92]. Notably, cilostazol use was found to have a dose-dependent association with reduced rate of dementia emergence (p for trend?=?0.001). Subgroup analysis identified a decline of dementia in cilostazol users with diagnosed ischemic heart disease (aHR 0.44, 95% CI 0.24?0.83) and cerebral vascular disease (aHR 0.34, 95% CI 0.21?0.54). These observations suggest that cilostazol use may reduce the risk to develop dementia, and a high cumulative dose further decreases the risk of dementia. These findings should be examined further in randomized clinical trials.Electronic supplementary material: The online version of this article (doi:10.1007/s13311-017-0512-4) contains supplementary material, which is available to authorized users. Twit Text FOAVip Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study ????Neurotherapeutics http://www.kidney.de/pget.php?&tw=1&pmid=28194663 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28194663 #FOAvip English Wikipedia <ref>{{Cite pmid|28194663}}</ref> Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study #MMPMID28194663 Tai SY; Chien CY; Chang YH; Yang YH Neurotherapeutics 2017[Jul]; 14 (3): 784-91 PMID28194663show ga Whether antiplatelet agents have a preventive effect on cognitive function remains unknown. We examined the potential association between the use of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, and the risk of dementia in an Asian population. Patients initiating cilostazol therapy between 1 January 2004 and 31 December 2009 without a prior history of dementia were identified from Taiwan's National Health Insurance database. Participants were stratified by age, sex, comorbidities, and comedication. The outcome of interest was all-cause dementia (ICD-9-CM codes 290.0, 290.4, 294.1, 331.0). Cox regression models were used to estimate the hazard ratio (HR) of dementia. The cumulative cilostazol dosage was stratified by quartile of defined daily doses using no cilostazol use as a reference. A total of 9148 participants 40 years of age or older and free of dementia at baseline were analyzed. Patients using cilostazol (n?=?2287) had a significantly decreased risk of incident dementia compared with patients not using the drug [n?=?6861; adjusted HR (aHR) 0.75; 95% confidence interval (CI) 0.61?0.92]. Notably, cilostazol use was found to have a dose-dependent association with reduced rate of dementia emergence (p for trend?=?0.001). Subgroup analysis identified a decline of dementia in cilostazol users with diagnosed ischemic heart disease (aHR 0.44, 95% CI 0.24?0.83) and cerebral vascular disease (aHR 0.34, 95% CI 0.21?0.54). These observations suggest that cilostazol use may reduce the risk to develop dementia, and a high cumulative dose further decreases the risk of dementia. These findings should be examined further in randomized clinical trials.Electronic supplementary material: The online version of this article (doi:10.1007/s13311-017-0512-4) contains supplementary material, which is available to authorized users. äCilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwi(epmc).pdf DeepDyve Pubget Overpricing